HECB-2100401

HECB-2100401 is a **small-molecule inhalation spray** drug candidate being developed by **Sunshine Lake Pharma** for **chronic obstructive pulmonary disease**. Publicly accessible pipeline-style sources identify it as a chemical drug and indicate that it entered **early clinical development in China**, but they do **not disclose a validated molecular target, mechanism of action, active ingredient identity, or INN** in the accessible records reviewed. Based on the available public evidence, it should currently be treated as a sponsor code for an investigational inhaled respiratory therapeutic rather than a fully characterized asset with publicly established pharmacology.